Randomised controlled trials, in both IgE-Mediated and Non-IgE Mediated CMA infants, demonstrate that Neocate Syneo effectively manages CMA symptoms1-4,9
Infants with a predisposition to atopy have delayed maturation of the Th1 response putting them at increased risk for infection in infancy and early childhood.12
Compared to children without cow’s milk allergy, significantly more children with cow’s milk allergy have been shown to experience infections and require antibiotic prescriptions, and at a significantly higher rate.13-18
- 35% lower rate of infections10*
- 47% lower rate of antibiotic prescriptions10*
- 56% reduction in hospitalisations due to infections4**,11
Healthcare professionals can request a tin of Neocate Syneo for professional evaluation†